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National trends in off-label use of atypical
antipsychotics in children and adolescents in the
United States
Minji Sohn (PhD)a,c,
∗
, Daniela C. Moga (MD, PhD)a,b, Karen Blumenschein (PharmD, MS)a, Jeffery Talbert (PhD)a
Abstract
The objectives of the study were as follows: to examine the national trend of pediatric atypical antipsychotic (AAP) use in the United
States; to identify primary mental disorders associated with AAPs; to estimate the strength of independent associations between
patient/provider characteristics and AAP use. Data are from the National Ambulatory Medical Care Survey and the National Hospital
Ambulatory Medical Care Survey. First, average AAP prescription rates among 4 and 18-year-old patients between 1993 and 2010
were estimated. Second, data from 2007 to 2010 were combined and analyzed to identify primary mental disorders related to AAP
prescription. Third, a multivariate logistic regressionmodel was developed having the presence of AAP prescription as the dependent
variable and patient/provider characteristics as explanatory variables. Adjusted odds ratios (AORs) with associated 95% confidence
intervals (CIs) were estimated. Outpatient visits including an AAP prescription among 4 to 18-year-old patients significantly increased
between 1993 and 2010 in the United States, and over 65% of those visits did not have diagnoses for US Food and Drug
Administration-approved AAP indications. During 2007 to 2010, the most common mental disorder was attention-deficit
hyperactivity disorder, accounting for 24% of total pediatric AAP visits. Among visits with attention-deficit hyperactivity disorder
diagnosis, thosewithMedicaid as payer (AOR 1.66, 95%CI 1.01–2.75), comorbidmental disorders (e.g., psychoses AOR 3.34, 95%
CI 1.35–8.26), and multiple prescriptions (4 or more prescriptions AOR 4.48, 95% CI 2.08–9.64) were more likely to have an AAP
prescription. The off-label use of AAPs in children and adolescents is prevalent in the United States. Our study raises questions about
the potential misuse of AAPs in the population.
Abbreviations: AAP = atypical antipsychotic, ADHD = attention-deficit/hyperactivity disorder, AOR = adjusted odds ratios, CI =
confidence interval, DSM = Diagnostic and Statistical Manual of Mental Disorders, FDA = Food and Drug Administration, ICD-9-CM
= International Classification of Diseases, Ninth Revision, Clinical Modification, NAMCS = National Ambulatory Medical Care Survey,
NCHS = National Center for Health Statistics, NHAMCS = National Hospital Ambulatory Medical Care Survey.
Keywords: adolescents, attention-deficit hyperactivity disorder, atypical antipsychotics, children, off-label
1. Introduction
Antipsychotic medications have long been used for the treatment
of mental disorders including psychosis, schizophrenia, and
bipolar disorder. These medications can be broadly categorized
into 2 classes: conventional antipsychotics, also known as first-
generation antipsychotics or typical antipsychotics, which were
discovered in the 1950s[1]; and atypical antipsychotics (AAPs)
(also known as second-generation antipsychotics), which were
introduced during the 1990. Compared with the conventional
antipsychotics, AAPs were marketed as reducing adverse side
effects such as extrapyramidal symptoms. As a result, AAPs were
extensively used not only for the US Food and Drug
Administration (FDA)-approved indications but also for other
conditions not approved. Off-label use is controversial given the
uncertainty regarding the effectiveness and safety of AAPs.[2–5]
Several postmarketing clinical trials reported serious adverse side
effects, including metabolic syndrome, cardiovascular events, or
death in AAP users.[6–8] Nevertheless, AAPs are one of the top-
selling classes of pharmaceuticals in the United States. In fact,
antipsychotic medications generated about $18.2 billion total
revenue in 2011, with 3 individual AAP agents accounting for
65% of the total revenue.[9] In children and adolescents in the
United States, AAPs are probably among the most increasingly
used classes of prescription drugs.[10,11] A study by Patel et al[11]
reported that AAP use in children and adolescents increased 1.5
to 3-fold between 1996 and 2001 in Medicaid programs. Olfson
et al[12] reported a 5-fold increase during 1993 to 2002 in
antipsychotic prescription for young patients. However, to the
best of our knowledge, there are no studies to analyze the recent
trends in pediatric off-label AAP use and to evaluate the role of
patient and provider characteristics associated with it. Therefore,
this study was aimed to examine the historical trend of AAP use
among 4 to 18-year-old patients in the United States; to assess the
characteristics of AAP use by identifying primary mental
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disorders; and to estimate the strength of independent association
of patient/provider characteristics with AAP prescription among
pediatric (4–18-year-old patients) attention-deficit hyperactivity
disorder (ADHD) visits.
2. Materials and Methods
2.1. Data source
Data sources for this study were the National Ambulatory
Medical Care Survey (NAMCS) and the National Hospital
Ambulatory Medical Care Survey (NHAMCS). The NAMCS
and NHAMCS are national surveys that collect cross-sectional
data on outpatient visits to nonfederal employed, office-based
physicians who are primarily engaged in direct patient care and
outpatient departments of noninstitutional general and short-
stay hospitals. We intended to estimate the national trend of
nonemergent visits relevant to an AAP prescription. For this
reason, we excluded data collected from hospital emergency
departments and ambulatory surgery centers.
The NAMCS/NHAMCS data include patient sociodemo-
graphic characteristics, physician information, up to 3 diagnoses
relevant to the visit, and drugs prescribed. Diagnoses are recorded
using the “International Classification of Diseases, Ninth
Revision, Clinical Modification” (ICD-9-CM). There were up
to 6 prescribed drugs recorded per visit during 1995 to 2002, and
up to 8 after 2003. To avoid overestimating the prescribing rate
and based on recommendations from the National Center for
Health Statistics (NCHS),[13] we only included the first 6 drugs
listed per visit during our study period—1995 to 2010.
Data from 1993 to 2010 were used to compute the average
annual rate of pediatric AAP prescriptions. Data from 2007 to
2010 were used to identify primary mental disorders related to
AAP use and to estimate independent association of patient/
provider characteristics with AAP prescription among ADHD
visits. Sample weights to account for sampling techniques were
applied in all analyses using Stata statistical software (version
12). For this study, ethical approval was not necessary because it
used public use data sets.
2.2. Definition of an AAP visit
An outpatient visit was regarded as an AAP visit if one or more
following medications were prescribed: risperidone, olanzapine,
quetiapine, ziprasidone, aripiprazole, paliperidone, asenapine,
and iloperiodone. For the period 1993 to 2005, AAPs were
identified using generic drug names as provided by the NCHS; for
after 2006, AAP use was identified based on Multum Lexincon
NAMCS/NHAMCS. Furthermore, AAP visits were categorized
into 2 groups based on the presence of one or more diagnosis
codes that corresponded to an US FDA-approved condition for
the prescription. During 1993 to 2010, AAPs were approved by
US FDA for the following 4 conditions: (1) schizophrenia (ICD-9-
CM, 295); (2) bipolar disorder (ICD-9-CM, 296.0; 296.1;
296.4–296.8); (3) depression (ICD-9-CM, 296.2; 296.3; 300.4;
311.X); and (4) autism (ICD-9-CM; 299.0). Figure 1 depicts US
FDA-approved indications for each AAP agent throughout
the study period. The US FDA approved olanzapine for
the manifestations of psychoses (ICD-9-CM; 290.XX-299.XX)
between 1996 and 2000. In 2000, the US FDA changed
the indication for olanzapine to schizophrenia and bipolar
disorder.
2.3. National trend of AAP visit (1993–2010)
As the first objective of the study, we examined the national trend
of AAP prescriptions by calculating average AAP visit rates
among 4 to 18-year-old patients for each survey year between
1993 and 2010. Based on significant changes related to AAP use
that occurred during the study period, we combined survey years
and formed 3 phases. Specifically, each phase began when US
FDA approved an additional indication for AAP use: (1) phase I
between 1993 and 1999, (2) phase II between 2000 and 2002,
and (3)phase III between 2003 and 2010. For each phase, we
examined whether there were newly available AAP agents or
additional US FDA warnings.
2.4. Mental diagnoses related with AAP visit (2007–2010
combined)
As the second objective of the study, we identified primary mental
disorders related to AAP use. For each AAP visit, we examined (1)
whether any mental diagnosis (ICD-9-CM, 290.XX-310.XX)
was present, (2) whether the mental diagnosis was for an US
FDA-approved indication (as defined above), and (3) what was
the first-listed mental diagnosis for the visit. For mental health
visits without an US FDA-approved indication, the first-listed
mental diagnosis was classified into following categories: (1)
psychoses with origin specific to childhood (“psychoses”
hereafter, ICD-9CM, 299.X); disturbances (ICD-9CM, 312.
XX; 313), (3) neurotic disorders (ICD-9CM, 300.0X; 300.1X,
Figure 1. US FDA-approved indications for atypical antipsychotics. US FDA, US Food and Drug Administration.
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300.2X, 300.3; 300.5; 300.8X; 300.9), and (4) other mental
disorders (ICD-9-CM, other codes between 290.XX-310.XX).
2.5. Factors associated with an AAP prescription in
pediatric ADHD visits (2007–2010 combined)
As the third objective of the study, the strength of independent
association of patient/provider characteristics with AAP pre-
scription among ADHD visits was estimated. Data from 2007 to
2010 were combined and analyzed to assess independent
associations of patient demographic/socioeconomic character-
istics (age, sex, race, region of residence, household income/
education level based on ZIP code, and payer source), physician
characteristics (provider type, metropolitan statistical area
located), and patients’ health information (presence of hyperac-
tivity, number of non-AAP drugs, other comorbidities) with an
AAP prescription among pediatric ADHD visits. A multivariate
logistic regression model was developed including these cova-
riates, and adjusted odds ratios (AORs) with associated 95%
confidence intervals (CIs) were estimated.
Among 4 to 18-year-old ADHD patient visits during 2007 to
2010, 4% had missing observations for variables that were based
on patient ZIP code, such as median household income and
percent of bachelor degree or higher. We did not include missing
observations in the analysis. However, we used imputed data for
observations missing a race variable. There were 29% missing
observations for the race variable, and we used NAMCS/
NHAMCS provided imputation values for those missing
observations. The method used by NAMCS/NHAMCS for
2007 and 2008 data to impute the race value was to use the
patient’s locality (ZIP code or state/county of residence),
physician locality, specialty, or 3-digit ICD-9-CM code for
primary diagnosis. If all failed to assign the race value, the
imputation was done based on a randomly selected record. For
2009 and 2010 data, race was imputed using a model-based,
single, sequential regression imputation method. The model for
imputing race is described in more detail in the 2009 to 2010
NAMCS/NHAMCS Public Use Data File Documentation.[14]
3. Results
3.1. National trend of AAP prescription
From 1993 to 2010, the overall AAP use showed an increasing
pattern (Fig. 2). Starting from 1995, the rate of AAP prescription
increased gradually until 1999. Between 1999 and 2000, the
average AAP prescription rate doubled, increasing from 0.4 per
100 visits to 0.9 per 100 visits. A similar pattern occurred
between 2002 and 2003when the average rate increased from 0.8
per 100 visits to 1.6 per 100 visits; after 2003, it showed a more
fluctuating pattern.
It seems that the rates of AAP prescription increased
significantly when the US FDA approved the drugs for
additional indications. During phase I (1993–1999), AAPs
were approved by the US FDA to treat schizophrenia; the
average AAP prescription rate for phase I was 0.15 per 100
visits (95% CI 0.1–0.21 per 100 visits). During phase II
(2000–2002), bipolar I disorder was added as a new indication
of AAPs; the average AAP prescription rate increased
significantly to 0.81 per 100 visits (95% CI 0.54–1.21 per
100 visits). During phase III (2003–2010), the US FDA
approved AAPs for more indications, including depression
and autism. The average AAP prescription rate during phase III
was 1.59 per 100 visits (95% CI 1.37–1.83), which is a
statistically significant increase from phase II.
Throughout the study period, a majority of AAP visits did not
include a diagnosis for US FDA-approved indications (referred to
as “off-indication” in Fig. 2). The off-indication visits accounted
for approximately 86% of pediatric AAP visits during 1995 to
2003, and 71% during 2004 to 2010. A statistically significant
increase for US FDA-approved AAP use was observed between
2003 and 2004 (P<0.001) when the US FDA approved 3 AAP
agents (aripiprazole, quetiapine, and ziprasidone) for bipolar
disorder in addition to their previously approved indication,
schizophrenia.
3.2. Mental diagnoses related to AAP visit
The estimated number of total AAP visits for pediatric patients
during 2007 to 2010 was 8,380,436 (weighted count), which
accounted for approximately 2% of the total pediatric outpatient
visits in the United States. Of those, 34% included one or more
diagnoses of US FDA-approved indications (Fig. 3). Within this
group, a majority of visits had diagnoses of bipolar disorder or
depression (16% and 14% of total pediatric AAP visits,
respectively), followed by autism and schizophrenia (5% and
1% of total pediatric AAP visits, respectively). Approximately
2% of total pediatric AAP visits had 2 or more diagnoses of US
FDA-approved indications.
Among those without any US FDA-approved indications,
ADHDwas the most common primary mental diagnosis (24% of
total pediatric AAP visits), followed by psychoses (14% of total
pediatric AAP visits). Disturbances and neurotic disorders took
up about 5% of total pediatric AAP visits, respectively.
Approximately 15% of total pediatric AAP visits did not include
any mental disorder diagnosis.
Figure 2. Atypical antipsychotic use in children and adolescents (age 4–18
years).
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3.3. Factors associated with an AAP prescription in
pediatric ADHD visits
During 2007 to 2010, the total number of pediatric ADHD visits
was estimated to be 31,501,209 (weighted count). Of those, 12%
included 1 or more AAP prescriptions. Characteristics of
pediatric ADHD visits are summarized in Table 1. Patient
demographics and healthcare provider characteristics were not
statistically different between AAP visits and non-AAP visits. A
significantly larger proportion of AAP visits had Medicaid as the
primary source of payment (52.50% vs 38.19%; P=0.0135).
Regarding ADHD characteristics, AAP visits were more likely to
have attention-deficit disorder with hyperactivity compared with
those without hyperactivity (58.76% vs 55.25%; P=0.010).
More drugs (excluding AAPs) were prescribed during AAP visits
as compared with non-AAP visits. Comorbidity profile was also
different in a way that AAP visits had more comorbid conditions
listed, including US FDA-approved AAP indications, psychoses,
neurotic disorder, disturbance, and diabetes.
In the multivariable logistic regression analysis, having
Medicaid as the primary payment source (AOR 1.66, 95%
CI 1.01–2.75), more non-AAP prescription medications (4 or
more prescriptions AOR 4.48, 95% CI 2.08–9.64), comorbid
mental disorders such as US FDA-approved AAP indications
(AOR 2.52, 95% CI 1.57–4.05), psychoses (AOR 3.34, 95% CI
1.35–8.26), neurotic disorder (AOR 2.67, 95% CI 1.27–5.61),
disturbance (AOR 3.60, 95% CI 1.94–6.69), and diabetes (AOR
14.21, 95% CI 1.77–114.28) significantly increased the odds of
having an AAP prescription in a pediatric ADHD-related visit
(Table 2). However, having comorbid obesity was negatively
associated with an AAP prescription (AOR 0.03, 95% CI
0.01–0.19).
4. Discussion
The purpose of this study was to examine the national trend of
pediatric AAP use in an outpatient treatment setting in the United
States. We estimated the average annual AAP prescription rates
between 1993 and 2010, and explored events related to AAPs.
Then, we identified mental diagnoses related to AAP prescription
for the period of 2007 to 2010. Lastly, we estimated the strength
of independent association of patient/provider characteristics
with AAP prescription among pediatric ADHD visits.
From 1993 and 2010, the overall AAP prescription rates in
pediatric outpatient visits showed an increasing pattern. There
was approximately 5-fold significant increase from phase I
(1993–1999) to phase II (2000–2002), and 2-fold increase from
phase II to phase III (2003–2010). As more AAP agents became
available and the US FDA approved more indications, AAP
prescription rates increased (Fig. 2). Also, it seemed that sudden
increases in AAP prescription rates were associated with an US
FDA approval for an additional AAP indication. During 1993 to
2010, all AAP agents entered the market by obtaining US FDA
approval for the treatment of schizophrenia. Other indications
including bipolar disorder, depression, and autism were added to
the label a few years later. Interestingly, during the year of 2000
when bipolar disorder was first indicated, there was an abrupt
increase in AAP prescription rates. Also, olanzapine was first
approved for treatment of depression in 2003 and there was
another abrupt increase in AAP prescription rates. Autism was
added to the label of risperidone in 2006, and the rate increase
was the highest since 2003. However, it is difficult to argue that
such increased prescription rates are mostly to treat the
additionally approved indication because the rate increased
not only for on-label but also for off-label. More specifically,
from phase I to phase II, AAP visits for US FDA-approved
indications increased only 0.09 per 100 pediatric outpatient
visits, whereas AAP visits for off-label uses increased 0.57 per 100
pediatric outpatient visits. Similarly, from phase II to phase III,
the magnitude of increase in off-label visits was larger than for US
FDA-approved indication visits (Fig. 2). Perhaps, having
approval for additional AAP indications impacted the AAP
therapy decision-making process in a way that AAPs were
regarded as useful for conditions other than currently approved
indications. Our analysis only intended to capture the national
trend, and further investigation using carefully designedmodels is
needed to clarify the association of a specific event with AAP
prescription rates.
Our analysis for identifying mental diagnoses that are related
to AAP prescriptions revealed that approximately 66% of total
pediatric AAP visits did not include a diagnosis for US FDA-
approved indications. Of those, ADHD was the most common
primary mental diagnosis. This finding is consistent with several
previous studies that examined pediatric AAP use. Pathak et al[7]
assessed the dispensing pattern of AAPs using ArkansasMedicaid
claims data and reported ADHD as the most common condition
for children and adolescents to be prescribed AAPs. Cooper
et al[15] reported the same finding from the NAMCS/NHAMCS
data between 1995 and 2002. In the study, approximately 15%
of total pediatric AAP visits did not include any mental diagnosis.
In a study by Staller et al, 77% of the outpatient antipsychotic
visits did not include a mental diagnosis. They collected medical
and prescription data from 8 outpatient clinics in Central New
York in 2002. The fact that they had amuch higher proportion of
psychiatric visits without a mental diagnosis than our study could
be explained by a number of factors, including different sampling
method, number of recorded diagnoses, or inclusion criteria in
defining antipsychotic visits. Nonetheless, our study, with
previous studies, raises a major issue about current antipsychotic
prescription pattern in which antipsychotic medications could
frequently be misused in pediatric population.
Figure 3. Mental diagnoses related to AAP visits. AAP, atypical antipsychotic.
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Table 1
Characteristics of pediatric ADHD visits.
AAP visits (n=3763) Non-AAP visits (n=27,738)
Baseline characteristics n % n % P
Age
Preschool child (age 4–5)† 179 4.76 1213 4.37 0.867
Elementary child (age 6–11)† 2026 53.84 17,081 61.58 0.085
Adolescent (age 12–18)† 1558 41.40 9445 34.05 0.089
Sex
Male 2768 73.56 19,587 70.62 0.498
Female 995 26.44 8151 29.38 0.498
Race
White 2948 78.34 22,427 80.85 0.449
Black 654 17.37 4289 15.46 0.507
Other 162 4.30 1021 3.68 0.744
Region of residence
Northeast 726 19.28 4876 17.58 0.681
Midwest 896 23.82 7160 25.81 0.700
South 1484 39.43 11,011 39.70 0.969
West 657 17.46 4690 16.91 0.916
Median household income in patient’s zip code
Quartile 1 1086 28.85 5886 21.22 0.160
Quartile 2 859 22.84 8292 29.89 0.067
Quartile 3 792 21.05 6106 22.01 0.837
Quartile 4 1026 27.26 7454 26.87 0.942
Percent population with Bachelor’s degree or higher in patient’s zip code
Quartile 1 1074 28.55 7648 27.57 0.853
Quartile 2 859 27.22 8292 22.52 0.181
Quartile 3 792 18.62 6106 26.19 0.105
Quartile 4 1026 25.61 7454 23.71 0.672
Metropolitan statistical area
No 487 12.93 5542 19.98 0.248
Yes 3277 87.07 22,195 80.02 0.248
Payer source
Private 1533 40.75 14,726 53.09 0.035
Medicaid 1976 52.50 10,593 38.19 0.013
Self-pay 296 7.87 1706 6.15 0.610
Other 1690 5.45 204 6.09 0.800
Mental health provider
No 1103 94.79 26,635 96.02 0.341
Yes 196 5.21 1103 3.98 0.341
Attention deficit disorder with hyperactivity
No 132 41.24 4040 44.75 0.010
Yes 3632 58.76 23,698 55.25 0.010
Number of non-AAP prescribed (different generic names)
0 322 8.56 3417 12.32 0.138
1 747 19.86 13,180 47.52 <0.001
2 1058 28.11 5607 20.21 0.007
3 836 22.22 3152 11.36 0.001
4+ 800 21.25 2382 8.59 <0.001
Comorbidities‡
US FDA-approved indications 970 25.77 2304 8.31 <0.001
Psychoses 321 8.53 547 1.97 <0.001
Neurotic disorder 466 12.39 1316 4.75 0.001
Adjustment disorder 88 2.33 435 1.57 0.304
Disturbance 886 23.55 1769 6.38 <0.001
Developmental disorder 177 4.70 799 2.88 0.358
Obesity 2 0.04 371 1.34 <0.001
Diabetes 7 0.18 4 0.01 0.008
Cardiovascular disease 0 0.00 10 0.04 0.611
AAP, atypical antipsychotic; ADHD, attention-deficit hyperactivity disorder.
 Data are given as weighted count of visits in thousands and percentage.
† These variables were tested as binary variables. That is, instead of testing as a single age variable with three categories, the 3 categories were tested individually as binary variables.
‡ These variables are not mutually exclusive.
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From our logistic regression model estimating the association
between several factors and AAP prescription in ADHD
patients, patient demographics and healthcare provider
characteristics did not show a significant relationship with
AAP prescription. Instead, patients’ medical profiles showed
much stronger associations with AAP prescription. More
specifically, having more coprescribed medications (i.e., other
than AAPs) and comorbid mental disorders, including US FDA-
approved AAP indications, psychoses, neurotic disorder, and
disturbance, increased the likelihood of having an AAP
prescription. This result indicates that an AAP is more likely
to be prescribed to ADHD patients when multiple health
conditions are present. Medicaid being a significant factor
could be explained with this result, because chronic illness and
other health risk factors are more prevalent among Medicaid
enrolees compared with those who are covered by private
insurance.[16–18]
Some limitations should be noted. First, the survey may not
capture sufficient information to estimate the AAP prescription
rates and characteristics of visits. We used 6 first-listed
medications and 3 diagnosis codes for the study period. Such
limited availability of medical/pharmacy records may have
misrepresented the true estimates in the study. For example, it
is possible that some AAP-treated patients had a severe physical
illness in addition to mental disorders, and due to the limited
space for the number of diagnosis codes on the survey form, their
healthcare providers were only able to record diagnoses for
physical illness. In this case, the visit data would have been
classified as an AAP visit with no mental disorder diagnosis code,
although the visit had a mental disorder diagnosis. Second, the
NAMCS/MHAMCS are designed to obtain the national/regional
estimate of outpatient healthcare service measures. State-level
estimates during the study period are unreliable, and we were
unable to assess the association of particular states with AAP
prescription rates. Third, due to the nature of micro visit level
data, the temporal relationship between explanatory variables
and AAP prescriptions was not identifiable. In other words, it is
not possible to conclude that having comorbid conditions
triggered the AAP use. Instead, we only observed that
comorbidities were associated with AAP use. Fourth, variables
of obesity, diabetes, and cardiovascular disease in our logistic
regression model had only a few observations, making the
estimated values unstable.
The findings of this study are from nonemergent outpatient
visits. Because our data source does not have hospital inpatient
data, we are apt to miss serious illness cases. This limitation could
lead to bias if hospitalized patients are exposed to AAPs at a rate
different from what is seen in the outpatient setting. For example,
we found that ADHD patients with another mental disorder
comorbidity were more likely to receive an AAP than those
without. Meanwhile, patients with comorbid mental disorders
such as schizophrenia or a mood disorder are more frequently
hospitalized,[19] indicating a possibility that hospitalized ADHD
patients may use AAPsmore often than outpatient patients. Thus,
without inpatient visit data, our analysis would have under-
estimated the true association.
To minimize potential confounding, we reported AORs after
controlling for a number of mental and physical comorbidities.
However, our regression is limited to variables that are
observable and measurable from the data source. Also, we
grouped comorbid mental disorders into smaller categories, such
as US FDA-approved indications, to estimate the overall impact
Table 2
Factors associated with atypical antipsychotic prescription.
Covariates
Adjusted
odds ratio
95% Confidence
interval
Age
Preschool child (age 4–5) Reference
Elementary child (age 6–11) 0.86 0.35–2.09
Adolescent (age 12–18) 1.11 0.49–2.53
Sex
Male Reference
Female 0.81 0.51–1.29
Race
White Reference
Black 0.86 0.48–1.55
Others 2.05 0.77–5.43
Region of residence
Northeast Reference
Midwest 0.84 0.40–1.75
West 0.84 0.38–1.84
South 0.90 0.43–1.89
Median household income in patient’s zip code
Quartile 1 Reference
Quartile 2 0.65 0.39–1.10
Quartile 3 0.79 0.38–1.65
Quartile 4 0.93 0.39–2.24
Percent population with Bachelor’s degree or higher in patient’s zip code
Quartile 1 Reference
Quartile 2 1.31 0.73–2.33
Quartile 3 0.77 0.31–1.88
Quartile 4 1.02 0.41–2.50
Metropolitan statistical area
Yes Reference
No 0.52 0.21–1.30
Payer source
Private Reference
Medicaid 1.66‡ 1.01–2.75
Self-pay 1.19 0.29–4.94
Other 1.08 0.38–3.09
Mental health provider
No Reference
Yes 0.77 0.31–1.92
Attention deficit disorder with hyperactivity
No Reference
Yes 3.00 0.75–11.93
Number of non-AAP prescribed (different generic names)
0 Reference
1 0.94 0.58–1.52
2 2.60‡ 1.38–4.90
3 3.06‡ 1.48–6.32
4+ 4.48‡ 2.08–9.64
Mental comorbidities
US FDA-approved indications 2.52‡ 1.57–4.05
Psychoses 3.34‡ 1.35–8.26
Neurotic disorder 2.67‡ 1.27–5.61
Adjustment disorder 1.21 0.57–2.58
Disturbance 3.60‡ 1.94–6.69
Developmental disorder 1.81 0.71–4.63
Physical comorbidities†
Obesity 0.03 0.01–0.19
Diabetes 14.21‡ 1.77–114.28
Cardiovascular disease Dropped
US FDA, US Food and Drug Administration.
 The variable of cardiovascular disease was dropped because it predicted no atypical antipsychotic
(AAP) use (AAP=0) perfectly.
† These variables are mutually exclusive.
‡ Significant at 5% significance level.
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of having those conditions, but we did not estimate the impact of
more specific disorders such as bipolar disorder or autism
spectrum disorder.
The identification of mental disorders in this study was done
through ICD-9-CM, although “Diagnostic and Statistical
Manual of Mental Disorders” (DSM) serves as a more reliable
resource for prescribing clinicians in the United States. For
ADHD, ICD criteria seem to be more stringent than DSM
criteria, as ICD criteria do not recognize some subtypes
of ADHD.[20,21] As a result, the prevalence of ADHD would
be much lower for an ICD-based diagnosis than for DSM-
based diagnosis.[22,23] Such discrepancies between ICD and DSM
relate to a potential misclassification. In the absence of DSM-
based diagnosis information, it is likely that the number of
ADHD cases from ICD-based records (reported as 24% of total
pediatric AAP visits) underestimates the number identified in
real practice.
Although our study covers the national trend until 2010,
several changes occurred in antipsychotic therapy and mental
disorder diagnosis during recent years. Several antipsychotic
agents were newly approved after 2010, and the introduction of
these agents would be expected to influence off-label antipsy-
chotic use. Also, mental disorder diagnostic criteria were revised
in DSM-V, which was published in 2013. One of the changes
made in the DSM-V, unlike the previous version (DSM-IV), is
that ADHD can be diagnosed alongside autism spectrum
disorder. Previously, the presence of autism spectrum disorder
ruled out ADHD. This change may further inflate the rate of AAP
prescription in ADHD patients. Nonetheless, caution is required
in implementing the findings of this study, because it may not
represent the current trend. Further investigation of recent
changes in psychiatry and the impact on AAP use is an area for
further investigation.
In conclusion, we show that AAP prescription rates in 4 to 18-
year-old patients significantly increased between 1993 and 2010
in the United States, and over 65% of those visits did not have a
diagnosis for US FDA-approved AAP indications. During 2007
to 2010, the most common mental disorder was ADHD,
accounting for 24% of total pediatric AAP visits. Among visits
with ADHD diagnosis, those with comorbid mental disorders
such as psychoses, neurotic disorder, and disturbance were more
likely to have an AAP prescription.
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